AME vs MIR: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: MIR is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AME and MIR share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AME and MIR exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

AMETEK is a Berwyn, Pennsylvania manufacturer of electronic instruments and electromechanical devices, founded in 1930 and employing roughly 22,500 people. It runs two segments. The Electronic Instruments Group (EIG) builds analytical, test and measurement, process and aerospace instrumentation, including power quality monitors, materials analysis systems and cockpit sensors. The Electromechanical Group (EMG) makes engineered electrical connectors and interconnects, precision motion components, thermal management products and, since the Paragon Medical acquisition, contract-manufactured medical instruments and implantable components. The common thread is niche leadership: AMETEK deliberately targets small, differentiated product categories where it can hold a top position and price for engineering content rather than compete on volume.

Full AME guide

Mirion Technologies (NYSE: MIR) designs and sells radiation detection, measurement, analysis and monitoring products across two segments: Nuclear & Safety, which serves nuclear power plants, defense, research labs and industrial customers, and Medical, which supports cancer-care delivery, medical diagnostics and practitioner radiation safety. The company came public through a 2021 SPAC merger and describes itself as the only pure-play public company of its scale in radiation measurement, giving investors combined exposure to the nuclear energy revival and advanced medical applications. Much of its value sits in a large installed base of equipment, dosimetry services and recurring aftermarket revenue.

Full MIR guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AME drivers: Record orders tied to AI infrastructure, aerospace and defense; The $5 billion Indicor instrumentation acquisition.
• MIR drivers: Nuclear power tailwind; Backlog and recurring revenue.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Valuation is the most immediate risk: at roughly 36 times trailing and about 26 times forward earnings, with an EV/EBITDA near 23.5, the shares price in continued execution and leave limited room for a demand air pocket. For MIR, mirion has a history of GAAP net losses, and reported earnings remain thin relative to its valuation (a trailing P/E above 170x on about $0.09 of EPS), so much of the story depends on adjusted figures.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AME if you believe its drivers more; MIR if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AME and MIR guides.

AME. As of October 16, 2026, AMETEK trades at a clear premium to the broader industrial group, with a trailing P/E near 36, a forward P/E near 26 and EV/EBITDA around 23.5. The premium reflects roughly 26 percent operating margins, steady free cash flow and a long record of accretive acquisitions rather than unusual top-line growth. The shares closed at $248.41 against a 52-week range of roughly $183 to $261 and an average analyst target near $282, with Q3 2026 results due November 3.

MIR. Mirion trades as a growth-oriented industrial where adjusted EBITDA and free cash flow, not GAAP EPS, anchor most valuation work given thin net income and heavy interest costs. After a roughly 35% fall in 2026 the stock sits near 23 times forward earnings and about 21 times EV to EBITDA, still a premium industrial multiple, while roughly $1.23 billion of debt keeps leverage in focus. Analysts had a mean price target of about $24 in mid-October 2026, well above the share price, and Zacks upgraded the stock to Buy in late September.

Headline figures (approximate, October 2026): AME shows revenue (ttm) ~$7.86B; Q2 2026 up ~15% YoY, operating margin ~26%, net income (ttm) ~$1.58B (~20% margin), q2 2026 sales / adj. eps ~$2.04B (+15%) / ~$2.09 vs ~$1.99 est.; MIR shows revenue (ttm) ~$1.02B, revenue (q2 2026) ~$267M (+~20% YoY), gross / operating margin (ttm) ~48% / ~7%, net income (ttm) ~$24.5M.

AME and MIR are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AME and MIR exposure against your real portfolio. It is not an investment adviser.